AWS and Bluesight have launched Prism, an AI system designed to help hospitals navigate 340B drug discount program compliance. Prism Assistant for ControlCheck, the initial product, reached general availability and currently operates across 20 health systems.
The 340B program allows eligible hospitals and health systems to purchase drugs at discounted prices, but compliance requirements are complex and enforcement penalties substantial. Hospitals struggle to track purchases across multiple systems and vendors, creating audit risk and operational friction.
Prism integrates pharmacy and compliance data across Bluesight's product suite, automating the manual work of cross-referencing purchases against 340B eligibility rules. The AI layer reduces the human effort required to demonstrate compliance during audits and helps hospitals avoid purchasing violations that trigger recoupment demands from manufacturers.
AWS provided cloud infrastructure and AI expertise for the project, leveraging its bedrock generative AI services. Bluesight built the domain-specific logic that understands 340B regulations and hospital pharmacy workflows. This partnership model reflects how healthcare vendors increasingly embed AI into compliance operations rather than treating it as a separate analytical layer.
The multi-product agent for broader 340B GPO compliance remains in development, suggesting Bluesight plans to expand Prism beyond single-hospital implementations to group purchasing organizations that aggregate buying across multiple institutions.
The move addresses a real operational gap. Hospital compliance teams currently rely on spreadsheets, manual audits, and external consultants to track 340B purchases. An AI system that continuously monitors transactions against program rules reduces audit preparation time and catches violations before they become costly recoupment events.
Success depends on data quality and regulatory accuracy. If Prism misses edge cases or misinterprets complex eligibility scenarios, hospitals could face greater liability. AWS and Bluesight will need robust validation against actual audit outcomes to prove the system reduces, rather than masks,